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Abstract
Background: Streptozotocin (STZ) is used as a common tool to induce diabetes and to study diabetes-induced
complications including diabetic peripheral neuropathy (DPN). Previously, we have reported that STZ induces a
direct effect on neurons through expression and function of the Transient receptor potential vanilloid 1 (TRPV1)
channel in sensory neurons resulting in thermal hyperalgesia, even in non-diabetic STZ-treated mice. In the present
study, we investigated the role of expression and function of TRPV1 in the central sensory nerve terminals in the
spinal cord in STZ-induced hyperalgesia in rats.
Results: We found that a proportion of STZ-treated rats were normoglycemic but still exhibited thermal
hyperalgesia and mechanical allodynia. Immunohistochemical data show that STZ treatment, irrespective of
glycemic state of the animal, caused microglial activation and increased expression of TRPV1 in spinal dorsal horn.
Further, there was a significant increase in the levels of pro-inflammatory mediators (IL-1b, IL-6 and TNF-a) in spinal
cord tissue, irrespective of the glycemic state. Capsaicin-stimulated release of calcitonin gene related peptide
(CGRP) was significantly higher in the spinal cord of STZ-treated animals. Intrathecal administration of
resiniferatoxin (RTX), a potent TRPV1 agonist, significantly attenuated STZ-induced thermal hyperalgesia, but not
mechanical allodynia. RTX treatment also prevented the increase in TRPV1-mediated neuropeptide release in the
spinal cord tissue.
Conclusions: From these results, it is concluded that TRPV1 is an integral component of initiating and maintaining
inflammatory thermal hyperalgesia, which can be alleviated by intrathecal administration of RTX. Further, the results
suggest that enhanced expression and inflammation-induced sensitization of TRPV1 at the spinal cord may play a
role in central sensitization in STZ-induced neuropathy.
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Background
STZ, a glucosamine-nitrosourea compound obtained
from Streptomyces achromogenes,i su s e da sa ne x p e r i -
mental tool to develop animal models to study diabetes
and associated complications that include diabetic per-
ipheral neuropathy (DPN). Several mechanisms, includ-
ing increase in oxidative/nitrosative stress have been
proposed for STZ-induced b-cell death. Further, the
ability of STZ to act as a NO donor has led many inves-
tigators to postulate that NO is involved in STZ-induced
b-cell death [1-3]. Recently, it has been proposed that
pancreatic b-cells are selectively sensitive to STZ,
because they contain higher levels of O-GlcNAc-selec-
tive N-acetyl-b-d-glucosaminidase (OGIcNAcase, an
enzyme responsible for attaching OGlcNAc to proteins)
than any other cell type [4-6]. STZ has been shown to
inhibit the enzyme OGlcNAcase, which causes cytotoxi-
city selectively to b-cells [4,6]. * Correspondence: lpremkumar@siumed.edu
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mechanical hyperalgesia in different animals models
[7,8]. It has been proposed that STZ-induced hypergly-
cemia contribute to the development of hyperalgesia
[7,9], but it is becoming evident that factors other than
hyperglycemia may be involved in development of early
hyperalgesia following STZ treatment [10-13]. Studies
have suggested that intracerebroventricular administra-
tion of STZ can cause behavioral alterations and
changes in brain pathology independent of changes in
b-cells [14]. Previous studies from our laboratory have
shown that STZ exerts a direct action on dorsal root
ganglion (DRG) neurons altering the expression and
function of TRPV1 via the reactive oxygen species
(ROS)-p38 Mitogen Activated Protein Kinase (MAPK)
pathway in mice [12]. In in-vitro studies, STZ-treated
neurons exhibited an increase in TRPV1-mediated cur-
rents through the ROS-mediated pathway. We further
observed that STZ also caused an increase in the phos-
phorylated form of p38 MAPK, suggesting that the
increase in the TRPV1 protein expression may involve
t h eR O S - p 3 8M A P Kp a t h w a y[ 1 2 ] .A l lt h e s ec h a n g e s
were independent of glycemic state of the animals.
There is growing evidence that supports a prominent
role of inflammation in the development and mainte-
nance of neuropathic pain. Microglia and astrocyte acti-
vation is observed in the spinal cord following PNS/
CNS injury and STZ-induced neuropathic pain [15-18].
Analgesic effect of inhibitors of phosphorylation of the
MAPKs and Extracellular Signal-regulated Protein
Kinase (ERK) [18-20] further substantiate the role of
inflammation in STZ-induced neuropathic pain. Acti-
vated microglia and their interaction with neurons in
spinal cord are associated with the development and
maintenance of neuropathic pain [21,22]. Enhanced
levels of pro-inflammatory cytokines and neuroinflam-
mation can sensitize TRPV1 and increase the pain sensi-
tivity [23,24]. On the other hand, stimulation of TRPV1
can mediate the release of pro-inflammatory cytokines,
neuropeptides (SP and CGRP), and glutamate through
influx of Ca
2+ in the activated microglia. These changes
may underlie the development of central sensitization
leading to neuropathic pain [25].
Resiniferatoxin (RTX) is a potent TRPV1 agonist and
its analgesic actions can be explained by its ability to
cause depolarization block of the peripheral or central
terminals in the short-term and nerve terminal ablation
in the long-term [26-29]. Earlier studies have shown
that intrathecal and intraganglionic administration of
RTX induced long-lasting analgesia suggesting the possi-
bility of nerve terminal ablation [27,29-31]. In dorsal
root ganglion and dorsal horn (DRG-DH) neuronal co-
cultures and in acute spinal cord or caudal spinal tri-
geminal nucleus slice preparations, RTX enhanced
frequency of spontaneous and miniature excitatory post
synaptic currents (mEPSCs), without affecting their
amplitude, suggesting a presynaptic locus of action
[27,32]. However, evoked synaptic currents were inhib-
ited due to slow and sustained activation of presynaptic
TRPV1 leading to depolarization block by maintaining
the Na
+ channels in an inactivated state at the central
sensory nerve terminals [27].
This study was undertaken to investigate the role of
TRPV1 expressed in the central sensory nerve terminals
of the spinal cord following intraperitoneal administra-
tion of STZ. We have found that STZ-induced thermal
and mechanical hyperalgesia were independent of glyce-
mic state of the animal. STZ exerted a direct effect by
inducing enhanced expression of TRPV1 and a resultant
increase in TRPV1-mediated neuropeptide release. STZ
also caused microglial activation in the spinal cord and
increased the levels of inflammatory mediators. Intrathe-
cal administration of RTX decreased TRPV1-mediated
neuropeptide release and alleviated thermal hypersensi-
tivity without affecting mechanical hypersensitivity.
Results
Role of intraperitoneal administration of STZ on various
metabolic parameters in rats
STZ is commonly used to induce diabetes in rodents to
study diabetes and related complications including DPN.
In this study, STZ (55 mg/kg, i.p.) was administered to
rats to induce diabetes. After 24 hour of STZ treatment,
60% animals were hyperglycemic (STZ-HG, n = 24/40)
(blood glucose levels > 300 mg/dl (range = 426-534 mg/
dl), whereas, rest of the animals were normoglycemic
(STZ-NG, n = 16/40) (blood glucose levels < 120 mg/dl
(range = 95-118 mg/dl). There was no change in the
glycemic state of animals over a period of 5 weeks
(Week 5: vehicle treated, 109.3 ± 3.13 (n = 5); STZ-HG,
496.4 ± 19.87 (n = 12); STZ-NG, 111.5 ± 2.98 mg/dl (n
= 8) (Figure 1A, 2A). Increase in body weight was inver-
sely correlated with the increase in blood glucose levels.
STZ-HG animals did not show a significant change in
the body weight over the 5 week period (Week 1, 323.2
±9 . 7v s .w e e k5 ,2 8 6 . 5±1 1 . 2g ,n=2 4 ) ,w h e r e a sS T Z -
NG animals showed significant increase in body weight
over the 5 week period (Week 1, 282.2 ± 4.3 vs. week 5,
380.3 ± 8.0 g, n = 16, p < 0.01), similar to that seen in
vehicle-treated animals (Week 1, 291.7 ± 4.0 vs. week 5,
396.4 ± 4.5 g, n = 10, p < 0.01) (Figure 1B, 2B). In order
to further confirm the glycemic status, we performed
glucose tolerance test (GTT) and measured plasma insu-
lin levels in vehicle-treated, STZ-HG and STZ-NG ani-
mals after 5 weeks. In a GTT, administration of glucose
(1 g/kg i.p.) significantly increased the blood glucose
levels (101.2 ± 3.1 vs. 220.0 ± 2.6 mg/dl, n = 6, p <
0.02) in vehicle-treated animals, which became normal
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remained significantly higher in STZ-HG group (> 500
mg/dl, n = 6, at all time points (0-2 h) (Figure 1C). In
STZ-NG group, i.p. administration of glucose (1 g/kg)
significantly increased blood glucose levels (101.2 ± 3.1
v s .2 7 0 . 0±4 0 . 9m g / d l ,n=6 ,p<0 . 0 1 ) ,a n dr e m a i n e d
higher than the vehicle-treated animals (Figure 2C) sug-
gesting a slightly compromised b-cell function. Plasma
insulin levels were significantly lower in STZ-HG ani-
mals as compared to vehicle-treated animals (vehicle
treated, 8.5 ± 1.0, STZ-HG, 2.0 ± 0.2 mg/ml, n = 6, p <
0.05) (Figure 1D). There was no significant difference in
insulin levels between STZ-NG and vehicle-treated ani-
mals (vehicle-treated, 8.5 ± 1.0, STZ-NG, 8.9 ± 1.1 mg/
ml, n = 6, ns) (Figure 2D). From these results, we con-
clude that STZ causes a substantial damage to pancrea-
tic b-cells indicated by the blood glucose levels and
GTT, whereas in a significant number of animals the b-
cell damage may not have been as severe indicated by
the blood glucose levels following GTT.
Intraperitoneal administration of STZ and early thermal
hyperalgesia and mechanical allodynia in rats
Next, in order to determine the effect of glycemic/meta-
bolic state on thermal hyperalgesia and mechanical allo-
dynia, we divided the animals in 3 different groups
(vehicle-treated, STZ-HG and STZ-NG). Interestingly,
w ef o u n dt h a tb o t hS T Z - H Ga n dS T Z - N Gg r o u p s
exhibited significant increase in thermal hyperalgesia as
compared to vehicle-treated animals after 1 week of
STZ treatment (vehicle, week 0: 10.2 ± 1.2 s;week 1:
11.8 ± 0.6 s, n = 6 (p > 0.05); STZ-HG, week 0: 11.0 ±
0.6 s; week 1: 7.8 ± 0.5 s, n = 12 (p < 0.05); STZ-NG,
w e e k0 :1 2 . 2±0 . 5s ;w e e k1 :9 . 4±0 . 4s ,n=8( p<
0.05) (Figure 1E, 2E). Animals were hyperalgesic over
the duration (5 weeks) of the study (vehicle, 11.3 ± 0.5
s; STZ-HG, 8.0 ± 0.3 s; STZ-NG, 9.2 ± 0.3 s (p < 0.05);
although towards the end there was a trend that hyper-
algesic state was reversing to become normal. Reports
from other laboratories and ours have suggested that
STZ causes an early phase of thermal hyperalgesia (upto
5-6 week) followed by a late phase of hypoalgesia (after
6 week) [12,33,34]. Mechanical allodynia developed after
3 weeks and the trend was similar in STZ-HG and STZ-
Figure 1 Changes in blood glucose levels, body weight,
glucose tolerance, plasma insulin level, thermal pain
sensitivity, mechanical allodynia in STZ-treated hyperglycemic
(STZ-HG) rats. A. Within a week after intraperitoneal injection of
STZ, blood glucose levels (BGL) significantly increased (p < 0.001)
and remained constant throughout the course of the experiment as
compared to vehicle-treated rats. B. The body weight of STZ-HG
rats (filled circles, n = 18) decreased, whereas body weight of
vehicle-treated rats (filled squares, n = 10) increased steadily over
the course of 5 weeks. C. Glucose tolerance test (GTT) in STZ-HG
and vehicle-treated rats 5 weeks after STZ administration. D. Plasma
insulin levels were significantly lower (p < 0.05) in STZ-HG rats as
compared to vehicle-treated rats. E. STZ-HG rats exhibited a
significant decrease in PWL (p < 0.05) as compared to vehicle-
treated rats. F. STZ-HG rats exhibited a significant (p < 0.05)
decrease in PWT after 3 weeks of STZ administration as compared
to vehicle-treated rats. Asterisks (*, **) represent p < 0.05 and p <
0.001, respectively.
Figure 2 Changes in blood glucose levels, body weight,
glucose tolerance, plasma insulin levels, thermal pain
sensitivity, mechanical allodynia in STZ-treated normoglycemic
(STZ-NG) rats. A. Blood glucose levels (BGL) remained constant
throughout the course of the experiment in STZ-NG and vehicle-
treated rats. B. The body weight of STZ-NG rats (filled circles, n =
12) and vehicle-treated rats (filled squares, n = 10) increased steadily
over the course of 5 weeks C. Glucose tolerance test (GTT) in STZ-
NG and vehicle-treated rats after 5 weeks of STZ administration. D.
Plasma insulin levels were unchanged in STZ-NG rats as compared
to vehicle-treated rats. E. STZ-NG rats exhibited a significant
decrease (p < 0.05) in PWL as compared to vehicle-treated rats. F.
STZ-NG rats exhibited a significant (p < 0.05) decrease in PWT after
3 weeks of STZ administration as compared to vehicle-treated rats.
Asterisk (*) represent p < 0.05.
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showed significant increase in mechanical allodynia as
compared to vehicle-treated animals (vehicle, week 0:
37.0 ± 1.8 g; week 5: 36.8 ± 1.6 g, n = 6(p > 0.05); STZ-
HG, week 0: 33.0 ± 1.8 g; week 5: 24.4 ± 2.0 g, n = 12
(p < 0.02); STZ-NG, week 0: 33.2 ± 1.7 g; week 5: 23.0
± 2.6 g, n = 8 (p < 0.02) (Figure 1F, 2F). It is generally
believed that thermal hyperalgesia and mechanical allo-
dynia are due to hyperglycemia. From our studies, it is
clear that early phase of thermal and mechanical hyper-
algesia is independent of glycemic state.
Intraperitoneal administration of STZ and microglial
activation and TRPV1 expression in spinal dorsal horn
In order to correlate the development of early phase of
thermal and mechanical hyperalgesia with the changes
in the spinal cord, we performed immunohistochemistry
to determine microglial activation (staining for OX-42)
and relative TRPV1 expression in spinal dorsal horn tis-
sue in vehicle-treated, STZ-HG and STZ-NG animals.
There are reports suggesting the involvement of inflam-
mation, microglial activation and increased TRPV1
expression and function in STZ-induced hyperalgesia
[12,16,18]. Following i.p. administration of STZ, the
intensity of OX-42 staining increased significantly in the
laminae I and II of spinal dorsal horn in both STZ-HG
and STZ-NG animals as compared to vehicle-treated
animals (Figure 3). STZ treatment also significantly
increased the TRPV1 staining in central terminals of
spinal dorsal horn as compared to vehicle-treated ani-
mals (Figure 4). The intensity of TRPV1 activation was
similar in both STZ-HG and STZ-NG animals. STZ-
induced microglial activation and increased TRPV1
expression in spinal dorsal horn is independent of glyce-
mic state of animals. These results suggest that the
effects are possibly due to direct actions of STZ rather
than as a result of hyperglycemia.
Intraperitoneal administration of STZ and spinal pro-
inflammatory cytokines
Next, we determined the role of pro-inflammatory
mediators in manifesting these responses. I.p. adminis-
tration of STZ significantly increased the levels of pro-
inflammatory cytokines (IL-1b,I L - 6 ,T N F - a)i nt h e
spinal cord homogenates of rats, which were not
related to the glycemic state of the animals (IL-1b:
vehicle,19.7 ± 1.9; STZ-HG, 26.8 ± 2.4; STZ-NG, 30.1
± 1.8 pg/mg protein, n = 5, p < 0.05, Figure 5A; IL-6:
vehicle, 6.3 ± 1.5; STZ-HG,15.6 ± 1.8; STZ-NG,12.3 ±
0.8 pg/mg protein, n = 5, p < 0.05, Figure 5B; TNF-a:
vehicle, 3.2 ± 0.5; STZ-HG, 7.9 ± 0.4; STZ-NG, 8.3 ±
0.8 pg/mg protein, n = 5, p < 0.05, Figure 5C. We sug-
gest that the increases in pro-inflammatory mediators
are due to microglial activation or increased TRPV1
expression in spinal dorsal horn, but not due to STZ-
induced hyperglycemic state.
TRPV1-mediated CGRP release and intraperitoneal
administration of STZ
As indicated earlier that both peripheral and central
terminals of the sensory neurons express TRPV1. Fol-
lowing the observation that STZ treatment increased the
intensity of TRPV1 staining in spinal dorsal horn, we
hypothesized that STZ administration might affect
Figure 3 Altered microglial activation in spinal cord dorsal
horn of STZ-treated rats. A. Representative images of OX-42
staining (marker for microglial activation) from a vehicle-treated,
STZ-HG and STZ-NG rats. B. Average gray values/10,000 μm
2 area of
OX-42 staining in spinal dorsal horn was significantly increased (p <
0.05) in both STZ-HG and STZ-NG rats as compared to vehicle-
treated rats. Asterisk (*) represents p < 0.05. Scale bar is 50 μm.
Figure 4 Altered TRPV1 staining in spinal cord dorsal horn of
STZ-treated rats. A. Representative images of TRPV1 staining from
a vehicle-treated, STZ-HG and STZ-NG rats. An enlarged segment
has also been shown. B. Average gray values/10,000 μm
2 area of
TRPV1 staining in dorsal horn was significantly increased (p < 0.05)
in both STZ-HG and STZ-NG rats as compared to vehicle-treated
rats. Asterisk (*) represents p < 0.05. Scale bar is 200 μm and 50 μm
for upper and lower panels, respectively.
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in central terminals of DRG neurons. TRPV1-mediated
CGRP release is a reliable assay to determine TRPV1
functions. The neuropeptide release was normalized to
the weight of the spinal cord tissue. STZ treatment did
not cause a significant change in basal CGRP release in
lumbar spinal region (vehicle,15.5 ± 0.9; STZ-HG,16.0 ±
2.1; STZ-NG, 19.65 ± 1.5 ng/g tissue/5 min, n = 5 (p >
0.05) (Figure 6A). However, STZ treatment significantly
increased capsaicin (10 μM)-evoked CGRP release in the
lumbar spinal cord tissue (basal vehicle, 15.5 ± 0.9,
evoked vehicle, 45.4 ± 3.6 (p < 0.05 as compared to
basal vehicle); evoked STZ-HG, 69.1 ± 3.2 (p < 0.05 as
compared to evoked vehicle); evoked STZ-NG, 95.3 ±
5.9 (p < 0.05 as compared to evoked vehicle) ng/g tis-
sue/5 min, (n = 5) (Figure 6B). The changes in basal
and capsaicin-evoked CGRP release were independent of
glycemic state of the animals and that these changes are
positively correlated with the expression of TRPV1 in
the spinal dorsal horn. In order to confirm the involve-
ment of TRPV1, we determined CGRP release following
intrathecal administration of RTX, which is known to
specifically target TRPV1 and abolish the effects
mediated by TRPV1. Intrathecal administration of RTX
prevented the increase in the capsaicin-evoked CGRP
release in STZ-treated animals (basal vehicle, 15.5 ± 0.9,
evoked vehicle, 45.4 ± 3.6 (p < 0.05 as compared to
basal vehicle); evoked STZ-HG (RTX-treated), 19.4 ±
2.8 (p > 0.05 as compared to evoked vehicle); evoked
STZ-NG, 25.6 ± 6.8 (p > 0.05 as compared to evoked
vehicle) ng/g tissue/5 min, (n = 5) (Figure 6C).
Role of intrathecal RTX on STZ-induced increase in
thermal and mechanical hyperalgesia
We hypothesize that STZ has a direct effect on TRPV1
expression and function in the central terminals of the
spinal cord. STZ-induced increase in microglial activa-
tion and pro-inflammatory mediator levels can alter the
expression levels or sensitize TRPV1, which can increase
the release of CGRP from the presynaptic sensory nerve
terminals. In the next set of experiments, we used RTX,
a potent TRPV1 agonist, when given intrathecally, can
specifically ablate TRPV1 expressing central terminals of
sensory neurons. In order to understand the role of
spinal TRPV1 in STZ-induced hyperalgesia, we adminis-
tered RTX (2 μg/kg/20 μl) intrathecally 2 weeks after
STZ treatment. RTX significantly prevented thermal
hyperalgesia in both STZ-HG (Week 5: vehicle,11.3 ±
0.5 s; STZ-HG,8.0 ± 0.3 s; STZ-HG (RTX-treated), 11.0
± 0.2 s, n = 12, p > 0.05) and STZ-NG animals (Week
5: vehicle,11.3 ± 0.5 s; STZ-NG,9.2 ± 0.3 s, STZ-NG
(RTX-treated),12.5 ± 0.60 s, n = 12, p > 0.05) (Figure
7A, B). Intrathecal RTX did not cause any change in
mechanical hypersensitivity in both STZ-HG (Week 5:
vehicle, 36.8 ± 1.6 g; STZ-HG,24.4 ± 2.0 g; STZ-HG
(RTX-treated),25.0 ± 2.3 g, n = 8, p < 0.05) and STZ-
NG animals (Week 5: vehicle,36.8 ± 1.6 g; STZ-HG,23.0
± 2.6 g; STZ-HG (RTX-treated), 26.4 ± 1.1 g, n = 8, p <
0.05) (Figure 7C, D), suggesting the involvement of
TRPV1 only in thermal hyperalgesia. This observation is
consistent with the findings that TRPV1 selectively med-
iates inflammatory thermal hypersensitivity, but not
mechanical hypersensitivity.
Discussion
In the present study, we have characterized the meta-
bolic state, release of inflammatory mediators, and
TRPV1 expression and function in the spinal cord fol-
lowing the administration of STZ. The major finding of
the study is that STZ-induced early phase of thermal
hyperalgesia (up to 5 weeks) is independent of glycemic
state and the ability of pancreatic b-cells to release insu-
lin, but is correlated with microglial activation
(increased OX-42 staining), increased TRPV1 expres-
sion, and increased levels of inflammatory mediators
(TNF-a,I L - 6 ,a n dI L - 1 b) in spinal cord. In both STZ-
Figure 6 Change in basal and capsaicin-evoked CGRP release
in STZ-treated rats A. Basal CGRP release in spinal dorsal horn
was unaffected after STZ treatment B. Both STZ-HG and STZ-NG
rats show a significant increase in the capsaicin evoked-CGRP
release C. Intrathecal RTX treatment prevent the increase in
capsaicin evoked-CGRP release in STZ-treated rats. Asterisks (*,
+)
represent p < 0.05 as compared to vehicle and evoked vehicle-
treated rats respectively.
Figure 5 Effect of intraperitoneal administration of STZ on
spinal pro-inflammatory cytokine levels. Interleukin-1b(IL-1b)(A),
Interleukin-6(IL-6)(B), Tumor necrosis factor-a (TNF-a)(C) in lumbar
spinal cord tissue homogenates. Asterisk (*) represent p < 0.05 as
compared to vehicle-treated rats.
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sal horn was significantly increased as shown by TRPV1
immunostaining and TRPV1-mediated CGRP-release.
Further evidence for the involvement of TRPV1 in early
phase of hyperalgesia was deciphered by the reversal of
thermal hyperalgesia, but not mechanical hyperalgesia
after intrathecal administration of RTX, a potent TRPV1
agonist that is known to ablate TRPV1 expressing nerve
terminals in the spinal cord [27,29-31,35].
Studies from other laboratories and ours have shown
differential sensitivity to administration of the same
dose of STZ within the same strain of animals
[12,36,37]. The reason for this difference is far from
clear. This could be due to differences in the expression
of b-cell-specific Glut-2 isoform of glucose transporter
(responsible for the b-cell-specific uptake of STZ) [37].
Final stages of STZ-induced cell death cascade involve
activation of islet cell poly (ADP-ribose) polymerase, the
expression levels of which may differ within a strain
[38]. Studies have also shown that time lapsed between
the last meal and STZ injection and the size of the pan-
creas could contribute to the variation. Other factors
that may be responsible include: insufficient concentra-
tion of STZ reaching the pancreas, faster recovery of
damaged pancreatic b-cells, and a decreased bioavailabil-
ity of STZ as a result of rapid metabolism and excretion.
In this study, we have observed a similar incidence of
developing hyperglycemia (60% hyperglycemic) following
STZ administration as seen with wild-type and age-
matched single transgenic mice (Ins-HA.D2 mice) [12].
The incidence of hyperglycemia could be correlated
with the changes in the body weight, plasma insulin
levels and glucose tolerance in these animals. Vehicle-
treated and STZ-NG rats showed a normal gain in the
body weight, whereas there was a significant decrease in
the body weight of STZ-HG rats, suggesting that STZ-
NG rats do not suffer from metabolic derangement.
There was no change in plasma insulin levels in STZ-
NG as compared to vehicle treated rats. It is interesting
to note that the blood glucose levels were slightly higher
following glucose tolerancet e s ti nS T Z - N Ga n i m a l s .
This suggests a compromised b- c e l lf u n c t i o ni nS T Z -
NG as compared to vehicle-treated rats.
T h ep r e s e n ts t u d yr e v e a l e dt h a tt h et i m ec o u r s ea n d
the degree of thermal and mechanical hypersensitivity
were similar in both STZ-HG and STZ-NG rats, regard-
less of their glycemic state. Thermal hyperalgesia was
evident within a week, whereas mechanical allodynia
was seen 3 weeks after STZ treatment. Interestingly, the
profile was similar in both STZ-HG and STZ-NG rats.
This has not been documented in the literature, may be
because of the common practice of excluding STZ-NG
animals from the studies or injecting a booster dose of
STZ. This observation raises a puzzling question
whether change in thermal and mechanical sensitivities
observed as a consequence of hyperglycemia or a direct
effect of STZ. Previously, we have reported this phe-
nomenon in mice and suggested that thermal hypersen-
sitivity observed in a mouse model could result from
the direct neuronal effects of STZ leading to enhanced
expression and function of TRPV1 receptor in DRG
[12]. There are evidences in the literature that hypergly-
cemia and hyperalgesia are not correlated [39]. Studies
have shown that < 40 to 60% of rats injected with STZ
were not hyperglycemic but exhibited mechanical hyper-
algesia [13,40,41]. Diabetes associated disturbance of
autonomic function and pain sensation in STZ-treated
animals were independent of glycemic factors or dyslipi-
demia [13]. Studies have shown a lack of correlation
between acute hyperglycemia and thermal hypersensitiv-
ity, warmth/cooling sensation, pressure pain, von Frey
filament thresholds or vibration perception thresholds
[40,42-44]. Furthermore, pain pressure thresholds in
type 2 diabetic Zucker rats could be corrected with
insulin-like-growth factor II (IGF-II) that has no effect
on blood glucose levels [45]. Based on our findings in
mice, we have proposed that a direct action of STZ
plays a role [12]. Therefore, we decided to focus on the
possible mechanisms underlying hyperalgesia.
STZ-treated rats exhibited microglial activation, indi-
cated by enhanced OX-42 staining and enhanced release
of pro-inflammatory cytokines in spinal cord. This was
Figure 7 Effect of intrathecal administration of RTX on STZ-
induced thermal hyperalgesia and mechanical allodynia. A.B.
RTX attenuated thermal hyperalgesia in both STZ-HG and STZ-NG
rats. C.D. RTX administration 2 weeks after STZ injection did not
have any effect on mechanical allodynia in both STZ-HG and STZ-
NG rats. Asterisks (*, #) represent p < 0.05 as compared to vehicle
treated and STZ-HG/STZ-NG rats respectively.
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that STZ-treated animals show microglial activation
[16,18]. In this study, we report for the first time that
STZ-NG animals show microglial activation. Further,
levels of IL-1b,I L - 6 ,a n dT N F - a in spinal cord tissue
were significantly higher in STZ-HG and STZ-NG ani-
mals. Microglial activation in spinal cord may cause
pro-inflammatory cytokine release. Several lines of evi-
dence suggest that cytokines have pro-nociceptive
actions, which are mediated by the sensitization of TRP
channels. The production and release of IL-6 by retinal
microglia as well as corneal and retinal epithelial cells is
partially dependent on the activation of TRPV1 [46-48].
IL-1b can induce pain hypersensitivity by activating
TRPV1-positive nociceptors via a p38-MAPK dependent
mechanism [49]. TNF-a m a yh a v eas i g n i f i c a n ti m p a c t
on nociceptive signaling at the spinal cord level,
mediated by increased responsiveness of presynaptic
TRPV1 receptors to endogenous agonists [23]. Long-
term exposure of primary afferent neurons to TNF-a
significantly increased the proportion of TRPV1-immu-
noreactive neurons [50]. TRPV1 activation increases
TNF-a receptor 1 expression in cultured mouse DRG
neurons through a ROS signaling pathway [51,52].
Further, C-C motif chemokine-2 (CCL2) is co-localized
with TRPV1 in the spinal dorsal horn [53,54]. Intrathe-
cal administration of CCL2 produced thermal hyperalge-
sia, which was inhibited by selective CCL2 receptor
antagonist (INCB3344) and a specific CCL2 neutralizing
antibody [54,55]. Upregulation of CCL2 receptor may
contribute to TRPV1 expressing neuronal excitability
[56]. TRPV1 may also be involved in releasing inflam-
matory agents from immune cells [15]. These studies
provide evidence that increased levels of pro-inflamma-
tory cytokines/chemokines can sensitize TRPV1 and at
t h es a m et i m eo v e re x p r e s s i o no fT R P V 1c a na u g m e n t
the release of these cytokines/chemokines. TRPV1
expression has been shown in microglia and astrocytes
[57]. TRPV1 activation on the microglia/neuronal term-
inals can lead to influx of Ca
2+ and cause glutamate and
CGRP release, which can subsequently activate glia
[27,28,32,58,59]. The interplay between microglial acti-
vation, increased expression/function of TRPV1 and
neurotransmitter/neuromodulator release may contri-
bute to central sensitization resulting in the develop-
ment of hyperalgesia.
Finally, we investigated whether TRPV1 expressed in the
central terminals of sensory neurons in the spinal cord is
involved in mediating thermal and mechanical hypersensi-
tivities seen in STZ-HG and STZ-NG animals. In order to
achieve this, we chose a specific TRPV1 agonist RTX,
which can selectively impair TRPV1, functions in the
spinal cord. Intrathecal RTX administration attenuated the
development of STZ-induced thermal hyperalgesia, but
had no effect on mechanical hypersensitivity. TRPV1 has
been shown to be involved only in inflammatory thermal
hypersensitivity, but not in mechanical hypersensitivity
[27,29,35,60,61]. Analgesic effects of localized application
of RTX can be explained by its ability to cause depolariza-
tion block of the peripheral or central nerve terminals in
the short-term and nerve term i n a la b l a t i o ni nt h el o n g -
term [26,27,32]. These observations further validate the
claim that TRPV1 is involved in inflammatory thermal but
not mechanical hypersensitivity.
Conclusions
In conclusion, we have shown in this study that STZ,
independent of its ability to cause b-cell damage and
hyperglycemia, can cause activation of microglia, and
release pro-inflammatory agents in spinal dorsal horn.
This further enhanced the expression of TRPV1 and
influx of Ca
2+, leading to the development of central
sensitization and contributest ot h e r m a lh y p e r a l g e s i a .
Attenuation of thermal hyperalgesia and TRPV1-
mediated CGRP release by intrathecal administration of
RTX confirm the role of TRPV1 in STZ-induced inflam-
matory thermal hyperalgesia.
Methods
STZ-administration
All procedures used in this study were approved by the
animal care and use committee at Southern Illinois Uni-
versity, School of Medicine, and conformed according to
National Institutes of Health and institutional guidelines.
Experiments were conducted on male Sprague Dawley
(275-300 g) rats purchased from Harlan laboratories
( I n d i a n a p o l i s ,I N ,U S A ) .R a t sw e r eh o u s e di ns p e c i f i c
pathogen-free barrier animal facility, and rodent labora-
tory chow (Laboratory Diet 5001; Nutrition Interna-
tional, Inc., Brentwood, MO) and drinking water were
provided ad libitum. Rat housing was maintained on a
12-h light/dark cycle at an ambient temperature of 22 ±
1°C. Freshly prepared STZ (55 mg/kg) in saline (pH 4.5
with 0.1 N citrate buffer) was injected intraperitoneally
as described previously [12,62]. Vehicle rats (n = 10)
received citrate buffered saline alone. In first set of
experiments, 20 animals were injected with STZ. Two
days after STZ injection, animals were divided in three
different groups on the basis of blood glucose levels;
vehicle (control animals treated with saline), STZ-hyper-
glycemic (STZ-HG) (blood glucose level > 300 mg/dl)
and STZ-normoglycemic (STZ-NG) (blood glucose level
< 120 mg/dl). After 5 week of blood glucose level mea-
surements and behavioural pain testing (per week) the
animals were sacrificed to carry out in-vitro studies. In
second set of experiments, 20 animals were injected
STZ to study the effect of RTX on STZ-induced hyper-
algesia. Glucose levels were determined with an
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Scan, Milpitas, CA) using whole blood obtained from
the tail.
RTX-administration
The experimental procedures especially in reference to
animals not experiencing unnecessary discomfort, dis-
tress, pain or injury have been approved by the South-
ern Illinois University School of Medicine Institutional
Animal Care and Use committee review panel in accor-
dance with the Panel of Euthanasia of American Veter-
inary Medical Association. Two days after STZ injection
animals were divided in three different groups as
described previously. Animals were tested for thermal
and mechanical sensitivities for 2 weeks (once/week).
After 2 weeks, rats in STZ-HG and STZ-NG groups
received intrathecal (L4/L5 intraspinal space) injection
of 2 μg/kg/20 μl of RTX in saline under isoflurane
anesthesia (2% oxygen) [29,63]. Control group received
a corresponding volume of vehicle. All the rats were
acclimatized to the test conditions 1 hour/day for 5 days
before starting the experiments.
Behavioural assays
Measurement of thermal sensitivity
Thermal nociceptive responses were determined using a
plantar test instrument (Ugo Basile, Camerio, Italy). The
rats were habituated (15 minutes acclimation period) to
the apparatus that consisted of three individual Perspex
boxes on a glass table. A mobile radiant heat source was
located under the table and focused onto the desired
paw. Paw withdrawal latencies (PWLs) were recorded
t h r e et i m e sf o re a c hh i n dp a wa n dt h ea v e r a g ew a s
taken as the baseline value. A timer was automatically
activated with the light source, and response latency was
defined as the time required for an abrupt withdrawal of
the paw. The apparatus has been calibrated to give a
normal PWL of approximately 10-12 s. In order to pre-
vent tissue damage, an automatic cut-off at 20 s was set.
Measurement of mechanical sensitivity
Mechanical nociceptive responses were assessed using a
dynamic plantar anesthesiometer instrument using von
Frey hairs (Ugo Basile, Camerio, Italy). Each rat was
placed in a chamber with a metal mesh floor and was
habituated (15 minutes acclimation period) to the appa-
ratus. A 0.5 mm diameter von Frey probe was applied
to the plantar surface of the rat hind paw with pressure
increasing by 0.5 g/s and the pressure at which a paw
withdrawal occurred was recorded and this was taken as
Paw Withdrawal Threshold (PWT). For each hind paw,
the procedure was repeated 3 times and the average
pressure to produce withdrawal was calculated. Succes-
sive stimuli were applied to alternating paws at 5 min
intervals. All the experiments involving behavioral
studies were performed by the experimenter who was
unaware of treatments.
Immunostaining
Five weeks after STZ injections, immunofluorescence
labeling of TRPV1 receptors and OX-42 (microglial mar-
ker) in spinal dorsal horn was performed on three vehi-
cle-treated, three STZ-HG and three STZ-NG rats to
determine the effect of STZ administration on TRPV1
receptor expression and microglial activation in spinal
dorsal horns. Rats were deeply anesthetized with i.p.
injection of ketamine (85 mg/kg) and xylazine (5 mg/kg)
and perfused intracardially with 100 ml ice-cold normal
saline followed by 150 ml 4% paraformaldehyde in 0.01
M PBS (pH 7.4). The lumbar segment of the spinal cord
were quickly removed and post-fixed for 2 hr in the same
fixative solution and cryoprotected in 20% sucrose in
0.01 M PBS for 24 hr at 4°C. Following cryoprotection,
15 μm sections were cut from lumbar portion of spinal
cords using a microtome (Leica CM 1850, North Central
Instruments Inc, Plymouth MN, USA).
For TRPV1 receptor and microglial marker (OX-42)
immunostaining, the sections were rinsed in 0.1 M PBS
and permeated with 1% triton X in 0.01 M PBS for 30
minutes. The sections were then blocked in 10% normal
donkey serum in PBS for another 30 minutes. The sec-
tions were then incubated overnight with the primary
antibody (TRPV1: Guinea anti-TRPV1 N terminal (dilu-
tion 1:1000) Neuromics, Minneapolis, MN, USA and
microglial activation marker: Mouse anti-CD11b (OX-
42) (dilution 1:100), Novus Biologicals, Littleton, CO,
USA) diluted in PBS containing 1% normal donkey
serum, 0.1% Triton X-100. Subsequently, sections were
rinsed in PBS and incubated (1 hour) with the second-
a r ya n t i b o d y( R h o d a m i n ed o n k e ya n t ig u i n e ap i gI g G
(dilution 1:50), Jackson Immunoresearch Laboratories,
PA, USA) diluted in PBS containing 1% normal donkey
serum, 0.1% Triton X-100. Sections were washed and
fixed. A confocal microscope (Specifications: Intensity-
20%, Gain-1(4 for microglia slides), Zoom-1, Offset-0,
Scan speed-150-160 seconds, Filter and color tool-nor-
mal) was used to view the sections, and areas of interest
were photo documented and quantified. The results
were expressed as average gray value/10,000 μms q u a r e
area. Three to five sections from 3 different animals
were analyzed.
Neuropeptide release assays
Tissue preparation
Five weeks after STZ injections, five rats from each
group i.e. vehicle-treated, STZ-HG, STZ-NG, STZ-HG
RTX treated, STZ-NG RTX treated were anesthetized
using isoflurane (5%) and oxygen. Spinal cord was col-
lected quickly by hydraulic method. Lumbar portion of
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synthetic interstitial fluid (SIF) (107.8 mM NaCl, 26.2
mM NaCO3, 9.64 mM Na-gluconate, 7.6 mM sucrose,
5.05 mM glucose, 3.48 mM KCl, 1.67 mM NaH2PO4,
1.53 mM CaCl2,0 . 6 9M g S O 4)g a s s e dw i t h9 5 %o x y g e n
and 5% carbon dioxide at 32°C. Three segments each of
0.10 g (range 0.05-0.15 g) from lumbar spinal cord of
each animal were taken for further elution studies (Bish-
noi et al., 2011).
Elution procedures and stimulation
A series of 3 glass tubes were filled with 0.5 ml SIF each
and positioned in a temperature controlled (32°C) shak-
ing bath. The release experiment was started by trans-
ferring the mounted spinal cord segments into the first
tube. After 5 min incubation, tissues were transferred to
the second tube for another 5 min and then moved to
the third tube containing capsaicin (10
-5 M, (8-methyl-
N-vanillyl-6-nonenamide, Sigma Aldrich, St Louis, MO,
USA) for 5 minutes. Capsaicin was prepared as stock
solutions in ethanol (100 mM for capsaicin) and diluted
to desired concentrations using physiological solution
prior to the experiments. The control experiments were
performed with the equivalent amounts of the solvent.
All the solutions were freshly prepared before the
experiments.
Enzyme immunoassays
For CGRP release assay, 100 μl of elutes were taken
from each tube. Spinal cord elutes were further centri-
fuged at 2000 rpm for 10 minutes. Samples were mixed
immediately after the incubation with 400 μl (1:4 dilu-
tion) of commercial CGRP EIA buffer containing several
protease inhibitors. The CGRP content was determined
immediately after the end of the experiment using com-
mercially available enzyme immunoassays (CGRP: Bertin
Pharma (formerly SPlbio), France, limit of detection =
0.7 pg/ml, range = upto 500 pg/ml). All EIA plates were
determined photometrically using a microplate reader.
Measurement of pro-inflammatory mediators in spinal
cord homogenates
Five weeks after STZ injections, five rats from each
group (vehicle treated, STZ-HG and STZ-NG) were
sacrificed. Spinal cord from each animal was collected
quickly by hydraulic method. Lumbar portion of spinal
cord were collected and cut into pieces. Tissues were
homogenized in cell-lysis buffer using hand homogeni-
zer and centrifuged. The supernatant was collected to
measure the levels of pro-inflammatory mediators (IL-
1b, IL-6, TNF-a) using respective ELISA kits (IL-1b, IL-
6, TNF-a:R a tI L - 1 b ELISA kit, Rat IL-6 ELISA kit and
Rat TNF-a ELISA kit were purchased from Invitrogen
Corporation, Camarillo, CA, USA) following manufac-
turer instructions.
Statistical analysis
Statistical analysis was performed using SPSS software.
Data are presented as mean ± SEM. Descriptive one
way analysis of variance (ANOVA) was used to compare
PWL and PWT at given time point for vehicle and/or
STZ and/or RTX treated animals. Descriptive one way
ANOVA followed by post hoc Tukey’s HSD was used to
compare more than 2 groups. A p value of < 0.05 was
considered as statistically significant.
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